AML

(redirected from Acute myeloid leukaemia)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.
Related to Acute myeloid leukaemia: Chronic myeloid leukaemia, Acute lymphoblastic leukaemia

Adjustable Rate Mortgage

A mortgage with an interest rate that changes periodically. Generally speaking, an adjustable rate mortgage is linked to some major benchmark rate; for example, the interest rate may be stated as "LIBOR + 1%." The mortgage may or may not have a cap on how much the interest rate can rise or fall, or on how often the interest rate may change. Very often, the initial interest rate for an adjustable-rate mortgage is lower than that for a fixed-rate mortgage. This allows more people to qualify for an adjustable-rate mortgage; however, this kind of mortgage can be risky because the interest rate (and therefore the monthly payment) can rise unexpectedly. Indeed the prevalence of ARMs has been blamed for the housing bubble in the mid-2000s and the subsequent recession. See also: Credit Crunch, Teaser Rate.

Anti-Money Laundering

Any law or regulation requiring an institution to perform due diligence on potential clients to ensure that it is not aiding in a money laundering scheme. If the institution does not conduct due diligence properly, it may be held legally liable for the money laundering activities. These regulations were an important part of the USA PATRIOT Act.

AML

See adjustable mortgage loan.
References in periodicals archive ?
Acute Myeloid Leukaemia Phase 3 Clinical Trial Pipeline Insights
Describing how the most common gene mutation found in acute myeloid leukaemia starts the process of cancer development, they suggested that three critical steps are required to transform normal blood cells into leukaemic ones, each subverting a different cellular process.
Reflecting a greater understanding of disease biology, the enthusiastic pursuit of Flt-3 inhibition in the development of novel acute myeloid leukaemia treatment has resulted in already crowded pipeline, with four products challenging for first-to-market status: Cephalons CEP-701, Novartis PKC-412, Millenniums MLN518 and Pfizers SU11248.
Nasdaq:BIVN) today announced that the Scientific Program Committee of the American Society of Clinical Oncology (ASCO) has selected Bioenvision's Evoltra(TM) (clofarabine) adult acute myeloid leukaemia (AML) data for oral presentation at its 2006 ASCO Annual Meeting.
Stefan Faderl, presented data at the meeting in which clofarabine was used as first-line treatment of acute myeloid leukaemia (AML) in adults.
for the treatment of adult and pediatric acute lymphoblastic leukaemia and acute myeloid leukaemia.
The filing was based on data from two pivotal Phase II trials in acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML) which will be presented at the 40th American Society of Clinical Oncology annual meeting in June.
E21R -- A modified form of GM-CSF, currently in Phase II in acute myeloid leukaemia.
Full browser ?